Stock PIRS PIERIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Pieris Pharmaceuticals, Inc.

Equities

PIRS

US7207952026

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
11.6 USD -2.77% Intraday chart for Pieris Pharmaceuticals, Inc. -6.60% -20.33%
Apr. 19 Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement MT
Apr. 03 North American Morning Briefing : Powell Awaited -2- DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Vicore Pharma's New CEO to Formally Take Office
Sweden’s Hansa Biopharma Appoints New Chief Scientific Officer
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Pieris to Cut 70% Workforce, Hires Advisor For Strategic Review; AstraZeneca to End R&D Deal
Pieris Pharmaceuticals to Explore Strategic Options
Pieris Pharmaceuticals, Inc. Announces Executive Changes
Sector Update: Health Care Stocks Steady to Higher Late Wednesday
Sector Update: Health Care
Top Midday Decliners
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday
Sector Update: Health Care
Pieris Pharmaceuticals Says AstraZeneca to Discontinue Phase 2a Trial of Asthma Treatment; Pieris Shares Fall Pre-Bell
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PIRS Stock
  4. News Pieris Pharmaceuticals, Inc.
  5. Other languages